GlassScriptPhysician profile
Mallory E Quesenberry
NPI 1568009488
$4,902.58
in general payments reported to CMS, 2019-2025
36 companies · $2,059 in 2025
The $2,059 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $371 · 2022: $697 · 2023: $760 · 2024: $1,015 · 2025: $2,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,834.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.12 | 2021-2025 | |
| Lilly USA, LLC | $694.91 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $686.91 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $509.35 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $350.87 | 2023-2025 | |
| Axsome Therapeutics, INC. | $196.47 | 2024-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $167.79 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $159.19 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $143.53 | 2023-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $119.48 | 2024-2025 | |
| Dexcom, INC. | $98.19 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.09 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Ardelyx, INC. | $79.64 | 2025 | Ibsrela |
| Organon LLC | $79.54 | 2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $76.77 | 2021-2023 | Belsomra, Steglatro |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $74.64 | 2024-2025 | General - Pain Management, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $66.57 | 2024 | Eliquis |
| Exact Sciences Corporation | $45.76 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $31.37 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lundbeck LLC | $29.80 | 2025 | Vyepti |
| Eisai INC. | $25.20 | 2025 | |
| Bioventus LLC | $24.13 | 2025 | Durolane |
| Genzyme Corporation | $23.48 | 2025 | |
| Neurelis, INC. | $22.32 | 2025 | Valtoco |
| Phadia US INC. | $19.90 | 2024 | Immunocap |
| Insulet Corporation | $19.08 | 2025 | Omnipod |
| Alnylam Pharmaceuticals INC. | $18.73 | 2023 | Amvuttra |
| Bausch Health US, LLC | $18.47 | 2025 | Aplenzin |
| Antares Pharma, INC. | $18.07 | 2025 | Xyosted |
| Fidia Pharma USA INC. | $17.96 | 2025 | Hymhyn |
| Janssen Pharmaceuticals, INC | $17.38 | 2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $15.49 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.93 | 2025 | Rexulti |
| Exeltis, USA INC. | $14.66 | 2024 | Slynd |
| Biohaven Pharmaceuticals, INC. | $14.25 | 2021 | |
| Corcept Therapeutics | $13.54 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Quesenberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.